GFAP and endophthalmitis: Normal inflammation; no ocular hypotony; 40% of patients experiences significant adverse effects: conjunctival erosion, hypotony, conjunctival dehiscence, presumed endophthalmitis, need for retacking; Increased expression of glial fibrillary acidic protein; fewer neurons and inflammatory reaction in the tack site